Steven H. Collis Sells 14,578 Shares of Cencora, Inc. (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR) Chairman Steven H. Collis sold 14,578 shares of the company’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares of the company’s stock, valued at $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cencora Stock Up 1.1 %

Shares of NYSE COR opened at $271.32 on Thursday. The company has a market capitalization of $52.61 billion, a P/E ratio of 38.59, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a 50 day simple moving average of $252.47 and a 200-day simple moving average of $240.68. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $271.86.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.81%. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of COR. 111 Capital acquired a new position in shares of Cencora in the 4th quarter worth approximately $716,000. Members Wealth LLC acquired a new position in Cencora during the fourth quarter worth $348,000. Centaurus Financial Inc. boosted its position in shares of Cencora by 37.5% during the fourth quarter. Centaurus Financial Inc. now owns 2,462 shares of the company’s stock worth $553,000 after buying an additional 672 shares during the period. Wood Tarver Financial Group LLC acquired a new stake in shares of Cencora in the fourth quarter valued at $136,000. Finally, Siemens Fonds Invest GmbH raised its holdings in shares of Cencora by 944.6% in the 4th quarter. Siemens Fonds Invest GmbH now owns 19,972 shares of the company’s stock valued at $4,645,000 after buying an additional 18,060 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Wells Fargo & Company raised their price objective on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a report on Friday, March 14th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average target price of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.